Inovio Pharmaceuticals Inc. closed 86.44% short of its 52-week high of $14.75, which the company achieved on April 1st.

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. Inovio ...

Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the fourth quarter of 2023. Inovio Pharmaceuticals reported earnings per share of -$1.10. This was above the analyst estimate for EPS ...

Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting ...

The company's lead product candidate, INO-4800, a DNA-based COVID-19 vaccine ... shares,' which allows you to own portions of stock without buying an entire share. For example, some stock ...

The promising data on INO-3107’s efficacy and safety further underpins Buchanan’s positive outlook for the company’s stock. TipRanks tracks over 100,000 company insiders, identifying the ...

They currently have a neutral rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on INO. Oppenheimer dropped their price objective on Inovio ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Free Report ... has a “Neutral” rating and a $3.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

Shares of Inovio Pharmaceuticals Inc. INO slid 4.78% to $1.99 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% ...